BioSolve Process supporting Economic Analysis of vein-to-vein Cell Therapy Processes
As cell therapy processes mature and advance further beyond clinical trials, the shift to the manufacture and supply of affordable therapies will become more important. These therapies are expensive. High cost of goods (COGs) can be a cause of commercial failure with cell therapies, so